Bryan Dunn, MD
Pulmonary Disease · Greenville, NCNPI 1972739811
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (34.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sanofi at 30.8% of the total.
Across 144 payments — averaging $85.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- Covidien LP$2K
- AstraZeneca$2K
- Medtronic$2K
- Olympus Corporation Of The Americas$1K
- GSK$392
- plus $1K from 19 others
Across 42 payments — averaging $8442.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$213K
- AstraZeneca$129K
- GSK$12K
What the payments were for
- Speaking & faculty fees$3,97832%
- Grants$320%
- Travel & lodging$4,17834%
- Food & beverage$3,97732%
- Education$1131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 3 | $3,786 |
| Covidien LP | 5 | $2,451 |
| AstraZeneca | 41 | $1,729 |
| Medtronic | 20 | $1,713 |
| Olympus Corporation Of The Americas | 10 | $1,075 |
| GSK | 21 | $392 |
| Genentech USA, Inc. | 5 | $155 |
| Merck | 8 | $132 |
| Amgen | 1 | $123 |
| AbbVie | 1 | $93 |
| United Therapeutics Corporation | 1 | $92 |
| Johnson & Johnson(2 entities) | 5 | $89 |
| Grifols USA, LLC | 5 | $86 |
| Boston Scientific | 2 | $82 |
| Boehringer Ingelheim | 4 | $67 |
| Mylan Specialty L.p. | 3 | $54 |
| Cook Incorporated | 1 | $32 |
| Shionogi Inc | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| Olympus America Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$3,728
- superDimension$2,356
- ILLUMISITE$1,287
- Olympus EBUS Bronchoscopes$856
- Olympus Capital Accessories$856
- Olympus Respiratory Accessories$856
- TEZSPIRE$495
- AIRSUPRA$250
- AREXVY$125
- FASENRA$125
How this compares
$12,277 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 241 | $173,386 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $18,027 |
| Spiriva RespimatTiotropium Bromide | 22 | $16,022 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,254 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,919 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,387 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,878 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $3,861 |
| Ventolin HfaAlbuterol Sulfate | 60 | $3,636 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,507 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $1,585 |
| Roflumilast | 13 | $655 |
| Prednisone | 179 | $455 |
| Montelukast Sodium | 73 | $450 |
| Esomeprazole Magnesium | 19 | $299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $392 | $191,413277 claims |
| Boehringer IngelheimSpiriva Respimat | $67 | $16,02222 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,729 | $12,17331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Greenville
- Ogugua ObiGreenville$16K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.